person

Esperanza L. R.

Country
Spain
Department
Oncology

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
0
Sites with multiple studies

Has run more than one trial at 0 of 13 partner sites.

Specializations

Advanced Lung Cancer Research

Focuses on Non‑Small Cell Lung Cancer subtypes, including EGFR‑mutated, KRAS‑mutated, ALK‑rearranged, and brain metastasis cases.

  • EGFR‑mutated NSCLC
  • KRAS G12C NSCLC
  • ALK‑positive NSCLC
  • NSCLC with brain metastases
  • Immunotherapy‑resistant NSCLC

Clinical activity is conducted at Hospital Universitario Lucus Augusti in Lugo.

Breast Cancer Therapeutics

Investigates HER2‑positive and triple‑negative breast cancer, spanning early‑stage high‑risk disease to metastatic settings.

  • HER2‑positive advanced breast cancer
  • PIK3CA‑mutated HER2+ disease
  • Triple‑negative breast cancer
  • Early breast cancer recurrence prevention
  • Hormone‑receptor‑positive HER2‑negative disease

Emphasis is placed on integrating targeted agents with chemotherapy.

Bladder and Urothelial Cancer

Dedicated to muscle‑invasive bladder cancer and high‑risk non‑muscle‑invasive disease, as well as advanced urothelial carcinoma.

  • Muscle‑invasive bladder cancer
  • BCG‑unresponsive NMIBC
  • HER2‑overexpressing urothelial cancer
  • FGFR‑altered urothelial carcinoma
  • Immunotherapy combinations in bladder cancer

Trials evaluate both intravesical and systemic therapeutic strategies.

Prostate Cancer Innovation

Targets castration‑resistant and castration‑sensitive disease, including aggressive variants.

  • Metastatic castration‑resistant prostate cancer
  • Aggressive variant prostate cancer
  • HRR‑deficient metastatic castration‑sensitive prostate cancer
  • Hormone‑naïve high‑risk prostate cancer
  • Novel androgen‑axis inhibitors

Research integrates genomic profiling for therapy selection.

Hematologic Malignancies

Covers multiple myeloma, lymphoma, and related plasma‑cell disorders.

  • Newly diagnosed multiple myeloma
  • Relapsed/refractory multiple myeloma
  • Diffuse large B‑cell lymphoma
  • Follicular lymphoma
  • MRD‑driven treatment strategies

High‑throughput flow cytometry is utilized for disease monitoring.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.